- Home
- BTMD vs CHRS Comparison
BTMD vs CHRS Comparison
Compare BTMD & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTMD
- CHRS
- Stock Information
- Founded
- BTMD 2012
- CHRS 2010
- Country
- BTMD United States
- CHRS United States
- Employees
- BTMD N/A
- CHRS N/A
- Industry
- BTMD Medicinal Chemicals and Botanical Products
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BTMD Health Care
- CHRS Health Care
- Exchange
- BTMD Nasdaq
- CHRS Nasdaq
- Market Cap
- BTMD 129.1M
- CHRS 112.5M
- IPO Year
- BTMD N/A
- CHRS 2014
- Fundamental
- Price
- BTMD $3.78
- CHRS $0.76
- Analyst Decision
- BTMD Strong Buy
- CHRS Buy
- Analyst Count
- BTMD 1
- CHRS 3
- Target Price
- BTMD $8.00
- CHRS $4.68
- AVG Volume (30 Days)
- BTMD 132.8K
- CHRS 1.2M
- Earning Date
- BTMD 08-07-2025
- CHRS 08-07-2025
- Dividend Yield
- BTMD N/A
- CHRS N/A
- EPS Growth
- BTMD 201.68
- CHRS N/A
- EPS
- BTMD 0.60
- CHRS N/A
- Revenue
- BTMD $199,379,000.00
- CHRS $272,251,000.00
- Revenue This Year
- BTMD $5.87
- CHRS N/A
- Revenue Next Year
- BTMD $8.59
- CHRS $132.69
- P/E Ratio
- BTMD $6.30
- CHRS $1.79
- Revenue Growth
- BTMD 6.44
- CHRS 19.87
- 52 Week Low
- BTMD $3.04
- CHRS $0.66
- 52 Week High
- BTMD $8.44
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- BTMD 50.21
- CHRS 40.42
- Support Level
- BTMD $3.44
- CHRS $0.74
- Resistance Level
- BTMD $4.25
- CHRS $0.90
- Average True Range (ATR)
- BTMD 0.23
- CHRS 0.05
- MACD
- BTMD 0.02
- CHRS 0.01
- Stochastic Oscillator
- BTMD 44.10
- CHRS 13.56
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.